Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;18(1):e8-e19.
doi: 10.1016/j.clcc.2018.09.003. Epub 2018 Sep 13.

Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy

Ryuma Tokunaga  1 , Shu Cao  2 , Madiha Naseem  3 , Jae Ho Lo  3 , Francesca Battaglin  4 , Alberto Puccini  3 , Martin D Berger  3 , Shivani Soni  3 , Joshua Millstein  2 , Wu Zhang  3 , Sebastian Stintzing  5 , Fotios Loupakis  6 , Chiara Cremolini  7 , Volker Heinemann  5 , Alfredo Falcone  7 , Heinz-Josef Lenz  3
Affiliations

Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy

Ryuma Tokunaga et al. Clin Colorectal Cancer. 2019 Mar.

Abstract

Background: Adenosine has an immunosuppressive and angiogenic modulation of the tumor microenvironment. The present study explored the efficacy of single nucleotide polymorphisms (SNPs) in adenosine-related molecules for patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy.

Patients and methods: We analyzed genomic DNA extracted from 451 samples from 3 independent cohorts: a discovery cohort of 107 patients treated with FOLFIRI (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) plus bevacizumab in FIRE-3 (ClinicalTrials.gov identifier, NCT00433927); a validation cohort of 215 patients with FOLFIRI plus bevacizumab in TRIBE (ClinicalTrials.gov identifier, NCT00719797); and a control cohort of 129 patients treated with FOLFIRI plus cetuximab in FIRE-3. The relationship between the selected SNPs and clinical outcomes was analyzed.

Results: In the discovery cohort, patients with any C allele in CD39 rs11188513 had significantly shorter median progression-free survival compared with those with the T/T variant (11.3 vs. 13.1 months; hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.04-2.77; P = .022) on univariate analysis. Also, their overall survival (OS) was shorter (27.4 vs. 49.9 months; HR, 2.10; 95% CI, 1.07-4.10; P = .031) on univariate and multivariable analyses. The significant association between CD39 rs11188513 and OS was confirmed in the validation cohort (25.8 vs. 31.6 months; HR, 1.53; 95% CI, 1.09-2.15; P = .013). CD73 rs2229523 and A2BR rs2015353 in the discovery cohort and CD39 rs2226163 in the validation cohort showed significant correlations with OS on univariate and multivariable analyses. None of SNPs were significant in the cetuximab control cohort.

Conclusion: Selected SNPs in the adenosine pathway could affect the clinical outcomes of patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab.

Keywords: A2AR; CD39; CD73; SNP; mCRC.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest:

The authors declare that they have no conflict of interest.

Figures

Figure 1.
Figure 1.
Mechanism of adenosine pathway in tumor microenvironment. Adenosine is autonomously produced from ATP through ADP via CD39 and CD73 expressed mainly on the surface of cancer cells, B cells or Tregs. The work of extracellular adenosine is mainly divided into two directions. For immune cells, adenosine has a potent immunosuppressive ability through A2AR and A2BR. For cancer cells, adenosine stimulates tumor growth and metastasis through A2BR. Abbreviations: CTL, cytotoxic lymphocyte; DC, dendritic cell; NK, natural killer; M2, M2 macrophage; MDSC, myeloid derived suppressor cell; Th1, T helper 1; Th17, T helper 17; Treg, regulatory T cell.
Figure 2.
Figure 2.
Overall survivals of patients with CD39 rs11188513 variants, T/T or any C (T/C or C/C), in the discovery cohort (A) and validation cohort (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hausler SF, Montalban del Barrio I, Strohschein J, et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 2011; 60:1405–18. - PMC - PubMed
    1. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257–65. - PMC - PubMed
    1. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 1998; 161:95–109. - PubMed
    1. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008; 1783:673–94. - PubMed
    1. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 2011; 11:201–12. - PMC - PubMed

Publication types

MeSH terms

Associated data